MedTrace Logo

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

NCT02990403 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2017-03-08

No results posted yet for this study

Summary

In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.

Conditions

  • Recurrent Pregnancy Loss

Interventions

DRUG

Aspirin

DRUG

Heparin

DRUG

Prednisone

DRUG

Immunoglobulin

DRUG

Dydrogesterone

Sponsors & Collaborators

  • Shanghai First Maternity and Infant Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-06-10
Completion
2018-12-22

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02990403 on ClinicalTrials.gov